Additional Guidance on 504 Certifications of No Adverse Change for January, February, and March 2021 Debenture Sales during the COVID-19 Emergency and Reminder About Catch-up Plans

The purpose of this Notice is to announce that, for the 504 loans that will be funded through the debenture sales scheduled in January, February and March 2021, the “COVID-19 Substantial Adverse Change Remedy Certification and Agreement (Rev May 2020)” (COVID-19 Agreement) will continue to be available when the Certified Development Company (CDC) has concluded that there has been a substantial adverse change in the Borrower’s ability to repay the Project financing since the submission of the 504 loan application to SBA.